The generation of human induced pluripotent stem cells (hiPSCs) derived from an autologous extraembryonic fetal source is an innovative personalized regenerative technology that can transform own-self cells into embryonic stem–like ones. These cells are regarded as a promising candidate for cell-based therapy, as well as an ideal target for disease modeling and drug discovery. Thus, hiPSCs enable researchers to undertake studies for treating diseases or for future applications of in utero therapy. We used a polycistronic lentiviral vector (hSTEMCCA-loxP) encoding OCT4, SOX2, KLF4, and cMYC genes and containing loxP sites, excisible by Cre recombinase, to reprogram patient-specific fetal cells derived from prenatal diagnosis for several genetic disorders, such as myotonic dystrophy type 1 (DM1), β-thalassemia (β-Thal), lymphedema-distichiasis syndrome (LDS), spinal muscular atrophy (SMA), cystic fibrosis (CF), as well as from wild-type (WT) fetal cells. Because cell types tested to create hiPSCs influence both the reprogramming process efficiency and the kinetics, we used chorionic villus (CV) and amniotic fluid (AF) cells, demonstrating how they represent an ideal cell resource for a more efficient generation of hiPSCs. The successful reprogramming of both CV and AF cells into hiPSCs was confirmed by specific morphological, molecular, and immunocytochemical markers and also by their teratogenic potential when inoculated in vivo. We further demonstrated the stability of reprogrammed cells over 10 and more passages and their capability to differentiate into the three embryonic germ layers, as well as into neural cells. These data suggest that hiPSCs-CV/AF can be considered a valid cellular model to accomplish pathogenesis studies and therapeutic applications.
Get full access to this article
View all access options for this article.
References
1.
AmendolaD., NardellaM., GuglielmiL., CerquettiL., CaricoE., AlesiV., PorruM., LeonettiC., BearziC., RizziR., D'AgnanoI., StiglianoA., NovelliG., and BucciB. (2014). Human placenta-derived neurospheres are susceptible to transformation after extensive in vitro expansion. Stem Cell Res. Ther., 5, 55.
2.
AoiT., YaeK., NakagawaM., IchisakaT., OkitaK., TakahashiK., ChibaT., and YamanakaS. (2008). Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science, 321, 699–702.
3.
BilousovaG., Jun duH., KingK.B., De LangheS., ChickW.S., TorchiaE.C., ChowK.S., KlemmD.J., RoopD.R., and MajkaS.M. (2011). Osteoblasts derived from induced pluripotent stem cells form calcified structures in scaffolds both in vitro and in vivo. Stem Cells, 29, 206–216.
4.
BottaA., TacconelliA., BagniI., GiardinaE., BonifaziE., PietropolliA., ClementiM., and NovelliG. (2005). Transmission ratio distortion in the spinal muscular atrophy locus: Data from 314 prenatal tests. Neurology, 65, 1631–1635.
5.
BottaA., BonifaziE., ValloL., GennarelliM., GarrèC., SalesiL., IraciR., SansoneV., MeolaG., and NovelliG. (2006). Italian guidelines for molecular analysis in myotonic dystrophy. Acta Myol., 25, 23–33.
6.
BrennandK.J., and GageF.H. (2011). Concise review: The promise of human induced pluripotent stem cell-based studies of schizophrenia. Stem Cells, 29, 1915–1922.
7.
BriceG., MansourS., BellR., CollinJ.R., ChildA.H., BradyA.F., SarfaraziM., BurnandK.G., JefferyS., MortimerP., and MurdayV.A. (2002). Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J. Med. Genet., 39, 478–483.
8.
CaoA., and GalanelloR. (2010). Beta-thalassemia. Genet. Med., 12, 61–76.
9.
CaoN., LiangH., HuangJ., WangJ., ChenY., ChenZ., and YangH.T. (2013). Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions. Cell Res., 23, 1119–1132.
10.
CareyB.W., MarkoulakiS., BeardC., HannaJ., and JaenischR. (2010). Single-gene transgenic mouse strains for reprogramming adult somatic cells. Nat. Methods, 7, 56–59.
11.
ChaeJ.I., KimD.W., LeeN., JeonY.J., JeonI., KwonJ., KimJ., SohY., LeeD.S., SeoK.S., ChoiN.J., ParkB.C., KangS.H., RyuJ., OhS.H., ShinD.A., LeeD.R., DoJ.T., ParkI.H., DaleyG.Q., and SongJ. (2012). Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem. J., 446, 359–371.
12.
ChenF., CaoJ., LiuQ., QinJ., KongJ., WangY., LiY., GengJ., LiQ., YangL., XiangA.P., and ZhangC. (2012). Comparative study of myocytes from normal and mdx mice iPS cells. J. Cell. Biochem., 113, 678–684.
De CoppiP., BartschG.Jr., SiddiquiM.M., XuT., SantosC.C., PerinL., MostoslavskyG., SerreA.C., SnyderE.Y., YooJ.J., FurthM.E., SokerS., and AtalaA. (2007). Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol., 25, 100-–106.
15.
DevineM.J., RytenM., VodickaP., ThomsonA.J., BurdonT., HouldenH., CavaleriF., NaganoM., DrummondN.J., TaanmanJ.W., SchapiraA.H., GwinnK., HardyJ., LewisP.A., and KunathT. (2011). Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat. Commun., 2, 440.
16.
DubowitzV., Van IddekingeB., RodeckC.H., CampbellS., SingerJ.D., ScheuerbrandtG., and MossD.W. (1978). Prenatal diagnosis in Duchenne muscular dystrophy: Salvage of normal male fetus. Lancet, 1, 90.
17.
EasleyC.A., MikiT., CastroC.A., OzolekJ.A., MinerviniC.F., Ben-YehudahA., and SchattenG.P. (2012). Human amniotic epithelial cells are reprogrammed more efficiently by induced pluripotency than adult fibroblasts. Cell. Reprogram., 14, 193–203.
18.
FanY., LuoY., ChenX., LiQ., and SunX. (2012). Generation of human β-thalassemia induced pluripotent stem cells from amniotic fluid cells using a single excisable lentiviral stem cell cassette. J. Reprod. Dev., 58, 404–409.
19.
FangJ., DagenaisS.L., EricksonR.P., ArltM.F., GlynnM.W., GorskiJ.L., SeaverL.H., and GloverT.W. (2000). Mutations in FOXC2 (MFH-1), a forkhead family distichiasis syndrome. Am. J. Hum. Genet., 7, 1382–1388.
20.
FerlosioA., ArcuriG., DoldoE., ScioliM.G., De FalcoS., SpagnoliL.G., and OrlandiA. (2012). Age-related increase of stem marker expression influences vascular smooth muscle cell properties. Atherosclerosis., 224, 51–57.
21.
FinegoldD.N., KimakM.A., LawrenceE.C., LevinsonK.L., CherniskeE.M., PoberB.R., DunlapJ.W., and FerrellR.E. (2001). Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum. Mol. Genet., 10, 1185–1189.
22.
GalendeE., KarakikesI., EdelmannL., DesnickR.J., KerenyiT., KhoueiryG., LaffertyJ., McGinnJ.T., BrodmanM., FusterV., HajjarR.J., and PolgarK. (2010). Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells. Cell. Reprogram., 12, 117–125.
23.
GeX, WangI.N., TomaI., SebastianoV., LiuJ., ButteM.J., Reijo PeraR.A., and YangP.C. (2012). Human amniotic mesenchymal stem cell-derived induced pluripotent stem cells may generate a universal source of cardiac cells. Stem Cells Dev., 21, 2798–2808.
24.
GreenR.L., LagacéR.E., OldroydN.J., HennessyL.K., and MuleroJ.J. (2013). Developmental validation of the AmpFℓSTR® NGM SElect™ PCR Amplification Kit: A next-generation STR multiplex with the SE33 locus. Forensic Sci. Int. Genet., 7, 41–51.
25.
GrodyW.W. (1999). Cystic fibrosis: Molecular diagnosis, population screening, and public policy. Arch. Pathol. Lab. Med., 123, 1041–1046.
26.
GrskovicM., JavaherianA., StruloviciB., and DaleyG.Q. (2011). Induced pluripotent stem cells-opportunities for disease modelling and drug discovery. Nat. Rev. Drug Discov., 10, 915–929.
27.
HannaJ., SahaK., PandoB., van ZonJ., LengnerC.J., CreyghtonM.P., van OudenaardenA., and JaenischR. (2009). Direct cell reprogramming is a stochastic process amenable to acceleration. Nature., 462, 595–601.
IsraelM.A., YuanS.H., BardyC., ReynaS.M., MuY., HerreraC., HefferanM.P., Van GorpS., NazorK.L., BoscoloF.S., CarsonC.T., LaurentL.C., MarsalaM., GageF.H., RemesA.M., KooE.H., and GoldsteinL.S. (2012). Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature, 482, 216–220.
32.
Itskovitz-EldorJ., SchuldinerM., KarsentiD., EdenA., YanukaO., AmitM., SoreqH., and BenvenistyN. (2000). Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol. Med., 6, 88–95.
33.
JangJ., YooJ.E., LeeJ.A., LeeD.R., KimJ.Y., HuhY.J., KimD.S., ParkC.Y., HwangD.Y., KimH.S., KangH.C., and KimD.W. (2012). Disease-specific induced pluripotent stem cells: A platform for human disease modeling and drug discovery. Exp. Mol. Med., 44, 202–213.
34.
JiaF., WilsonK.D., SunN., GuptaD.M., HuangM., LiZ., RobbinsR.C., KayM.A., LongakerM.T., and WuJ.C. (2010). A nonviral minicircle vector for deriving human iPS cells. Nat. Methods., 7, 197–199.
35.
KadariA., LuM., LiM., SekaranT., ThummerR.P., GuyetteN., ChuV., and EdenhoferF. (2014). Excision of viral reprogramming cassettes by Cre protein transduction enables rapid, robust and efficient derivation of transgene-free human induced pluripotent stem cells. Stem Cell Res. Ther., 5, 47.
36.
KarumbayaramS., NovitchB.G., PattersonM., UmbachJ.A., RichterL., LindgrenA., ConwayA.E., ClarkA.T., GoldmanS.A., PlathK., Wiedau-PazosM., KornblumH.I., and LowryW.E. (2009). Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells, 27, 806–811.
37.
KrishnanA.V., and KiernanM.C. (2006). Axonal function and activity-dependent excitability changes in myotonic dystrophy. Muscle Nerve, 33, 627–636.
38.
LenschM.W., SchlaegerT.M., ZonL.I., and DaleyG.Q. (2007). Teratoma formation assays with human embryonic stem cells: A rationale for one type of human-animal chimera. Cell Stem Cell, 1, 253–258.
39.
LiC., ZhouJ., ShiG., MaY., YangY., GuJ., YuH., JinS., WeiZ., ChenF., and JinY. (2009). Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Hum. Mol. Genet., 18, 4340–4349.
40.
LuH.E., TsaiM.S., YangY.C., YuanC.C., WangT.H., LinX.Z., TsengC.P., and HwangS.M. (2011). Selection of alkaline phosphatase-positive induced pluripotent stem cells from human amniotic fluid-derived cells by feeder-free system. Exp. Cell Res., 317, 1895–1903.
41.
MackD.L., GuanX., WagonerA., WalkerS.J., and ChildersM.K. (2014). Disease-in-a-dish: The contribution of patient-specific induced pluripotent stem cell technology to regenerative rehabilitation. Am. J. Phys. Med. Rehabil., 93 (11 Suppl 3), S155–S168.
42.
MarkoulakiS., HannaJ., BeardC., CareyB.W., ChengA.W., LengnerC.J., DausmanJ.A., FuD., GaoQ., WuS., CassadyJ.P., and JaenischR. (2009). Transgenic mice with defined combinations of drug-inducible reprogramming factors. Nat. Biotechnol., 27, 169–171.
43.
MostoslavskyG., KottonD.N., FabianA.J., GrayJ.T., LeeJ.S., and MulliganR.C. (2005). Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol. Ther., 11, 932–940.
44.
MoxleyR.T., CorbettA.J., MinakerK.L., and RoweJ.W. (1984). Whole body insulin resistance in myotonic dystrophy. Ann. Neurol., 15, 157–162.
45.
MunsatT.L., and DaviesK.E. (1992). International SMA consortium meeting: 26–28 June 1992; Bonn, Germany. Neuromuscul. Disord., 2, 423–428.
46.
NizzardoM., SimoneC., FalconeM., LocatelliF., RiboldiG., ComiG.P., and CortiS. (2010). Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells. Cell. Mol. Life Sci., 67, 3837–3847.
47.
OhiY., QinH., HongC., BlouinL., PoloJ.M., GuoT., QiZ., DowneyS.L., ManosP.D., RossiD.J., YuJ., HebrokM., HochedlingerK., CostelloJ.F., SongJ.S., and Ramalho-SantosM. (2011). Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat. Cell Biol., 13, 541–549.
48.
OldJ., Traeger-SynodinosJ., GalanelloR., PetrouM., and AngastiniotisM. (2005). Prevention of Thalassemias and Other Hemoglobin Disorders, vol. 2. Laboratory Methods. Nicosia, Cyprus: Thalassemia International Federation (TIF).
49.
OsafuneK., CaronL., BorowiakM., MartinezR.J., Fitz-GeraldC.S., SatoY., CowanC.A., ChienK.R., and MeltonD.A. (2008). Marked differences in differentiation propensity among human embryonic stem cell lines. Nat. Biotechnol., 26, 313–315.
50.
PappB., and PlathK. (2013). Epigenetics of reprogramming to induced pluripotency. Cell, 152, 1324–1343.
ParkI.H., ZhaoR., WestJ.A., YabuuchiA., HuoH., InceT.A., LerouP.H., LenschM.W., and DaleyG.Q. (2008b). Reprogramming of human somatic cells to pluripotency with defined factors. Nature, 451, 141–146.
53.
PrasadV.K., and KurtzbergJ. (2008). Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant., 41, 99–108.
54.
QuX., LiuT., SongK., LiX., and GeD. (2012). Induced pluripotent stem cells generated from human adipose-derived stem cells using a non-viral polycistronic plasmid in feeder-free conditions. PLoS One, 7, e48161.
55.
RovelliA.M., and StewardC.G. (2005). Hematopoietic cell transplantation activity in Europe for inherited metabolic diseases: Open issues and future directions. Bone Marrow Transplant., 35 (Suppl 1), S23–S26.
56.
SangiuoloF., D'ApiceM.R., BrusciaE., LucidiV., and NovelliG. (2002). Towards the pharmacogenomics of cystic fibrosis. Pharmacogenomics, 3, 75–87.
57.
ShiJ., ShiW., NiL., XuX., SuX., XiaL., XuF., ChenJ., and ZhuJ. (2013). OCT4 is epigenetically regulated by DNA hypomethylation of promoter and exon in primary gliomas. Oncol. Rep., 30, 201–206.
58.
Sholto-Douglas-VernonC., BellR., BriceG., MansourS., SarfaraziM., ChildA.H., SmithA., MellorR., BurnandK., MortimerP., and JefferyS. (2005). Lymphoedema-distichiasis and FOXC2: Unreported mutations, de novo mutation estimate, families without coding mutations. Hum. Genet., 117, 238–242.
59.
SomersA., JeanJ.C., SommerC.A., OmariA., FordC.C., MillsJ.A., YingL., SommerA.G., JeanJ.M., SmithB.W., LafyatisR., DemierreM.F., WeissD.J., FrenchD.L., GadueP., MurphyG.J., MostoslavskyG., and KottonD.N. (2010). Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells, 28, 1728–1740.
60.
SommerC.A., StadtfeldM., MurphyG.J., HochedlingerK., KottonD.N., and MostoslavskyG. (2009). Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells, 27, 543–549.
61.
SommerC.A., SommerA.G., LongmireT.A., ChristodoulouC., ThomasD.D., GostissaM., AltF.W., MurphyG.J., KottonD.N., and MostoslavskyG. (2010). Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells, 28, 64–74.
62.
SpitalieriP., CorteseG., PietropolliA., FilaretoA., DolciS., KlingerF.G., GiardinaE., Di CesareS., BernardiniL., LauroD., ScaldaferriM.L., CitroG., NovelliG., De FeliciM., and SangiuoloF. (2009). Identification of multipotent cytotrophoblast cells from human first trimester chorionic villi. Cloning Stem Cells, 11, 535–556.
63.
SpitalieriP., QuitadamoM.C., OrlandiA., GuerraL., GiardinaE., CasavolaV., NovelliG., SaltiniC., and SangiuoloF. (2012). Rescue of murine silica-induced lung injury and fibrosis by human embryonic stem cells. Eur. Respir. J., 39, 1.
64.
SutkowskaE., GilJ., StembalskaA., Hill-BatorA., and SzubaA. (2012). Novel mutation in the FOXC2 gene in three generations of a family with lymphoedema-distichiasis syndrome. Gene, 498, 96–99.
65.
TakahashiK., OkitaK., NakagawaM., and YamanakaS. (2007). Induction of pluripotent stem cells from fibroblast cultures. Nat. Protoc., 2, 3081–3089.
66.
TiemannU., MarthalerA.G., AdachiK., WuG., FischedickG.U., Araúzo-BravoM.J., SchölerH.R., and TapiaN. (2014). Counteracting activities of OCT4 and KLF4 during reprogramming to pluripotency. Stem Cell Rep., 2, 351–365.
67.
TiscorniaG., VivasE.L., and Izpisúa BelmonteJ.C. (2011). Diseases in a dish: Modeling human genetic disorders using induced pluripotent cells. Nat. Med., 17, 1570–1576.
68.
TrounsonA., ShepardK.A., and DeWittN.D. (2012). Human disease modeling with induced pluripotent stem cells. Curr. Opin. Genet. Dev., 22, 509–516.
69.
WirthB. (2000). An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum. Mutat., 15, 228–237.
70.
WuM., ChenG., and HuB. (2013). Induced pluripotency for translational research. Genomics Proteomics Bioinformatics, 11, 288–293.
71.
YamanakaS. (2008). Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif., 41 (Suppl 1), 51–56.
72.
YeL., ChangJ.C., LinC., SunX., YuJ., and KanY.W. (2009). Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc. Natl. Acad. Sci. USA, 106, 9826–9830.
73.
YuJ., VodyanikM.A., Smuga-OttoK., Antosiewicz-BourgetJ., FraneJ.L., TianS., NieJ., JonsdottirG.A., RuottiV., StewartR., SlukvinI.I., and ThomsonJ.A. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318, 1917–1920.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
